INVA NASDAQ
Credit Risk of going bust: lower than 82% of companies Debt: 15.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.21 (down 99%), Innoviva, Inc. would be worth roughly what it owes.
Total debt $269.7M against a stock market value of $1.52B.
Distance to default 10.25 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $129.2M (short-term plus half of long-term), stock volatility 27.0%; Altman Z'' 9.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Burlingame, CA 94010
US
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Zhen Marianne | F-InKind | 1,127 | $21.00 | 2026-08-20 |
| Basso Stephen | F-InKind | 558 | $21.00 | 2026-08-20 |
| Raifeld Pavel | F-InKind | 1,130 | $21.00 | 2026-08-20 |
| Basso Stephen | F-InKind | 559 | $22.24 | 2026-05-20 |
| Raifeld Pavel | F-InKind | 1,130 | $22.24 | 2026-05-20 |